Health
Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences
Astellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences. The deal features $285 million that covers the upfront fee and a payment that becomes due if the ...
- Published
- (1 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 36-word snippet. The full article is at the source.
More from Endpoints News and around the same time
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetesEli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabetes rather than obesity. The drug…Anthropic buys a single-person biotech startup backed by Atlas VentureThe AI company Anthropic has acquired a drug discovery startup called Mithril Medicine, as part of its push into the life sciences. And that's where things start to get strange. Mithril is ...Backed by Amish and Mennonites, a new kind of gene therapy company takes shapeLANCASTER, PA — This spring, Lorraine and Mark Martin, a Mennonite family with a tax business, adopted a stubby-legged cow named Royal Lite. Lorraine, Mark and Royal Lite all have one thing in common: They ...Draft COINS rules could threaten broad China collaborationsThe release of draft regulations from the Treasury Department has spurred an intense debate over the future of China biotech deals, which could be sharply curtailed under the proposal as written. The draft bars US ...Lilly's ads can continue after Novo challenge, judge rulesNovo Nordisk has suffered another setback in its uphill battle against Eli Lilly in the booming obesity drug market after a US judge rejected its attempt to block television ads that Novo alleges are misleading. ...Gubra looks beyond metabolism, hopes for first portfolio company this yearThe Copenhagen-based drugmaker Gubra's present is mostly about obesity. Its future will need to be about a much broader pipeline. The company has a portfolio of weight loss drug candidates but is moving into the ...This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
